Short answer
Stereotaxis, Inc. (STXS) filed an 8-K current report with the SEC on November 10, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.02 (Results of Operations and Financial Condition), Item 2.03 (Creation of a Direct Financial Obligation), Item 3.02 (Unregistered Sales of Equity Securities), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). $12.0M initial convertible note financing closed, with potential additional proceeds up to $12.0M.
Stereotaxis, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $12.0M initial convertible note financing closed, with potential additional proceeds up to $12.0M
- Notes carry 10% annual interest, mature November 9, 2029, and generally defer interest through payment-in-kind accrual
- $1.21 conversion price for Initial Notes, set at a 30% premium to the prior 10-day VWAP
- Financing introduces dilution risk, capped at 20,070,290 shares, or 19.9% of pre-financing shares
- Proceeds fund working capital, commercialization acceleration, research and development, and general corporate needs
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results announced by Stereotaxis on November 10, 2026
- Full results and management commentary available in Exhibit 99.1, the earnings press release
Item 2.03 · Creation of a Direct Financial Obligation
- Item 2.03 confirms new indebtedness through the Notes referenced under Item 1.01
- Debt terms, principal amount, interest rate, maturity and use of proceeds require review of Item 1.01
- Notes create direct financial obligations that may increase leverage and future cash-interest requirements
Item 3.02 · Unregistered Sales of Equity Securities
- Private issuance of Notes and related shares under the Note Financing, outside a public offering
- Financing completion and additional draws remain subject to required regulatory approvals
- Potential equity dilution from shares issued with the Notes
- Proceeds intended to support Stereotaxis and acquired Robocath operations, subject to execution risks
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $8.9M, up 20% year over year and 16% sequentially, led by system revenue growth to $3.0M
- Recurring revenue $5.9M, up 6% year over year but down 4% sequentially amid catheter supply constraints
- Gross margin 45%, with recurring revenue margin 59% versus system margin 15%, highlighting profitability dependence on recurring sales
- Adjusted operating loss $5.1M and negative cash flow $6.5M, including $3.9M of Robocath acquisition payments
- Liquidity pressure: cash $4.0M at September 30, supplemented by $12M convertible-note proceeds and potential additional $12M draw
Item EX-99.2 · Exhibit EX-99.2
- Up to $24 million convertible financing: $12 million upfront plus $12 million available after regulatory milestones
- 10% annual interest, accrued until maturity in three years, increasing future cash obligations
- Conversion price $1.21 per share, a 30% premium to the prior 10-day VWAP, limiting immediate dilution unless converted
- Pro forma cash $16 million, with total potential availability of $28 million including the optional draw
- Proceeds support working capital, commercialization acceleration, research and development, and general corporate needs
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Stereotaxis, Inc. 8-K filings
Get the next STXS 8-K as it lands
Follow STXS for push alerts, or ask the research agent what this filing means.